Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 variant-dependent inflammasome activation.
Teyssou E, Marot S, Gothland A, Malet I, Zafilaza K, Leducq V, Cocherie T, Todesco E, Soulié C, Marcelin AG, Calvez V. Teyssou E, et al. Among authors: zafilaza k. J Infect. 2023 Jul;87(1):62-63. doi: 10.1016/j.jinf.2023.04.005. Epub 2023 Apr 13. J Infect. 2023. PMID: 37060923 Free PMC article. No abstract available.
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: zafilaza k. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Henry-Bolland W, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: zafilaza k. medRxiv [Preprint]. 2023 May 30:2023.05.25.23290512. doi: 10.1101/2023.05.25.23290512. medRxiv. 2023. PMID: 37398037 Free PMC article. Preprint.
Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies.
Leducq V, Zafilaza K, Fauchois A, Ghidaoui E, Sayon S, Dorival C, Meledje ML, Lusivika-Nzinga C, Yordanov Y, Martin-Blondel G, Carrat F, Marcelin AG, Soulie C; COCOPREV Study Group. Leducq V, et al. Among authors: zafilaza k. J Infect Dis. 2023 Nov 23:jiad523. doi: 10.1093/infdis/jiad523. Online ahead of print. J Infect Dis. 2023. PMID: 37996072
Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.
Guilbaud R, Franco Yusti AM, Leducq V, Zafilaza K, Bridier-Nahmias A, Todesco E, Soulie C, Fauchois A, Le Hingrat Q, Kramer L, Goulenok T, Salpin M, Daugas E, Dorent R, Ottaviani S, Zalcman G, Ghosn J, Choquet S, Cacoub P, Amoura Z, Barroux B, Pourcher V, Spano JP, Louet M, Marcelin AG, Calvez V, Charpentier C, Descamps D, Marot S, Ferré VM, Coppée R. Guilbaud R, et al. Among authors: zafilaza k. J Infect Dis. 2024 Apr 12;229(4):1041-1049. doi: 10.1093/infdis/jiad499. J Infect Dis. 2024. PMID: 37956413
Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G, Marcelin AG, Soulié C, Kaisaridi S, Lusivika-Nzinga C, Zafilaza K, Dorival C, Nailler L, Boston A, Ronchetti AM, Melenotte C, Cabié A, Choquet C, Trinh-Duc A, Lacombe K, Gaube G, Coustillères F, Pourcher V, Martellosio JP, Peiffer-Smadja N, Chauveau M, Housset P, Piroth L, Devaux M, Pialoux G, Martin A, Dubee V, Frey J, Le Bot A, Cazanave C, Petua P, Liblau R, Carrat F, Yordanov Y. Martin-Blondel G, et al. Among authors: zafilaza k. Clin Microbiol Infect. 2023 Apr;29(4):543.e5-543.e9. doi: 10.1016/j.cmi.2022.12.016. Epub 2022 Dec 28. Clin Microbiol Infect. 2023. PMID: 36586513 Free PMC article.
Phylodynamics of SARS-CoV-2 in France, Europe, and the world in 2020.
Coppée R, Blanquart F, Jary A, Leducq V, Ferré VM, Franco Yusti AM, Daniel L, Charpentier C, Lebourgeois S, Zafilaza K, Calvez V, Descamps D, Marcelin AG, Visseaux B, Bridier-Nahmias A. Coppée R, et al. Among authors: zafilaza k. Elife. 2023 Apr 26;12:e82538. doi: 10.7554/eLife.82538. Elife. 2023. PMID: 37159510 Free PMC article.
Long-term evolution of humoral immune response after SARS-CoV-2 infection.
Teyssou E, Zafilaza K, Sayon S, Marot S, Dropy M, Soulie C, Abdi B, Tubach F, Hausfater P, Marcelin AG, Boutolleau D; SEROCOV study group. Teyssou E, et al. Among authors: zafilaza k. Clin Microbiol Infect. 2022 Jul;28(7):1027.e1-1027.e4. doi: 10.1016/j.cmi.2022.03.012. Epub 2022 Mar 17. Clin Microbiol Infect. 2022. PMID: 35307573 Free PMC article.
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, Jary A, Dorgham K, Bruel T; Sorbonne Université SARS-CoV-2 Neutralizing Antibodies Study Group; Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Marot S, et al. Among authors: zafilaza k. Nat Commun. 2021 Feb 8;12(1):844. doi: 10.1038/s41467-021-21111-9. Nat Commun. 2021. PMID: 33558507 Free PMC article.
20 results